Gland Pharma Limited delivered impressive financial results for the third quarter ended December 31, 2025, demonstrating strong operational performance and sustained growth momentum across its global operations. The pharmaceutical company's Board of Directors approved the unaudited financial results at their meeting held on January 28, 2026.

Financial Performance Highlights

The company's consolidated financial performance showed remarkable strength across multiple parameters. Revenue from operations reached ₹16,953.63 million for Q3 FY26, representing a substantial 22% year-on-year increase from ₹13,840.52 million in Q3 FY25. This growth trajectory continued for the nine-month period, with revenues of ₹46,878.60 million compared to ₹41,915.95 million in the corresponding period of the previous year, marking a 12% increase.

Profitability and Margin Expansion

The company demonstrated strong profitability improvements with adjusted EBITDA margins of 26% for Q3 FY26 and 25% for the nine-month period. Adjusted profit before tax (PBT) reached ₹3,865 million in Q3 FY26, showing a 29% year-on-year growth, while the adjusted PBT margin improved to 23% from 22% in the previous year. The company's gross profit margin remained healthy at 66% for the quarter, reflecting efficient cost management and operational leverage.

Exceptional Items and Regulatory Impact

During Q3 FY26, the company recognized an exceptional item of ₹243.46 million related to additional provisions for gratuity and leave liability following the Government of India's notification of four Labour codes on November 21, 2025. These codes consolidate 29 existing Labour Laws, and the company has made appropriate provisions based on draft rules and available information.

Corporate Governance Updates

The Board of Directors approved the reappointment of M/s. Grant Thornton Bharat LLP as Internal Auditors for the financial year 2026-27, effective from April 1, 2026. Grant Thornton Bharat LLP, a member of Grant Thornton International Ltd, is described as a leading professional services firm providing assurance, consulting, tax, risk and digital transformation services across industries and sectors.

Business Development and Market Performance

The company's performance was supported by strong execution across key markets including the US and Europe. Management highlighted double-digit growth in core markets, with Cenexi achieving breakeven and contributing to consolidated performance. The company continues to focus on new product launches, CDMO contract ramp-ups, and operational efficiencies to strengthen its market position in the global injectable pharmaceuticals segment.

Gland Pharma has reported a significant 62% month-on-month increase in exports, marking a substantial improvement in the company's international business performance. This growth reflects the pharmaceutical company's strengthening position in global markets and its ability to expand its international operations effectively.

Export Performance Highlights

The company's export performance shows remarkable momentum with the reported month-on-month growth figures:

Market Implications

This substantial export growth indicates Gland Pharma's successful expansion in international pharmaceutical markets. The 62% month-on-month increase demonstrates the company's operational capabilities and market penetration strategies in global markets.

The strong export performance reflects the company's ability to meet international demand and maintain competitive positioning in the pharmaceutical sector. This growth trajectory suggests effective execution of the company's international business strategy and operational excellence in export operations.

Business Development

The significant month-on-month export increase positions Gland Pharma favorably in the competitive pharmaceutical landscape. This performance indicates the company's capacity to scale its international operations and capitalize on global market opportunities effectively.